BIOCARDE

Biosensing and surface characterization using a Cavity-Ring-Down Ellipsometer

Coordinatore	FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Greece [EL]
Totale costo	192˙436 €
EC contributo	150˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-07-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS  Organization address address: N PLASTIRA STR 100 city: HERAKLION postcode: 70013 contact info Titolo: Ms. Nome: Zinovia Cognome: Papatheodorou Email: send email Telefono: +30 2810 391522 Fax: +30281 391555	EL (HERAKLION)	hostInstitution	150˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'We propose to construct a pre-commercial microsecond-resolved, spectrally broadband, ellipsometer, based on our recently-developed, ERC-funded technique of cavity-ring-down ellipsometry (CRDE), for which we have a US and international (PCT) patents pending. This BIOCARDE instrument will have unprecedented time resolution and sensitivity, compared to commercial ellipsometers, and will have potential application in the biosensing and surface characterization (semiconductor) industries. The BIOCARDE instrument will be tested by the Biosensors group at FORTH (Prof. Gizeli), and by our industrial partners SOPRALAB in Paris (world-leading ellipsometry company). Interest in the instrument will be from three directions: 1) Research groups in the biosensing and surface characterization fields. Instruments will be sold to these groups, which will increase the profile and research scope of CRDE. 2) SOPRALAB, is interested in the enabling technologies of the instrument (the combination of the broad-band laser and microsecond-resolved data acquisition) 3) Biosensing companies, as the BIOCARDE instrument will be made to be compatible with (and tested with) their commercial prisms and biosensing delivery systems, to prove that the new capabilities (microsecond ellipsometric detection) is compatible with their existing technologies.'